Anthropic launches Claude Science and will develop its own drugs
Anthropic launched Claude Science, a research workbench for drugmakers, and said it will run its own internal drug-discovery programs rather than only licensing Claude to pharma partners. The move pushes Anthropic from AI supplier toward drug developer, positioning it against the same pharma companies it sells tools to — though no disease focus, dollar figure, or timeline was disclosed.
Source: statnews.com ↗
what it should be doing besides training models and building products
Eric Kauderer-Abrams, Anthropic head of life sciences
Why this matters
- → AI lab moves into drug development, competing directly with pharma clients
- → Tests Claude's real-world utility beyond software and licensing models
- → Signals confidence in AI-assisted discovery despite unproven timeline
AI maker becomes drug maker